News

Generative AI in Healthcare Investments in Next 2 Years!

💡 AI Dominating Life Sciences Investments:

  • A survey indicates that 60% of life sciences companies plan to invest in AI and machine learning (ML) in the next two years.

🤖 AI in Pharmaceuticals, Traditional vs. Generative AI:

  • AI/ML is prevalent in pharmaceuticals, with a distinction between conventional AI/ML and Generative AI in Healthcare (GenAI).
  • GenAI, exemplified by ChatGPT, is gaining prominence rapidly, holding potential to accelerate drug discovery and enhance innovation.

🌐 Regulatory Challenges for AI Implementation:

  • Regulatory acceptance poses a core challenge in implementing AI in pharmaceuticals.
  • Authorities are yet to answer fundamental questions related to AI submissions, testing, and evidence requirements.

💰 Cost Barriers and Perceived Risks:

  • The cost of implementing GenAI in the pharmaceutical space is currently high.
  • Concerns about hallucinations (incorrect outputs) exist, but the pharmaceutical industry aims for human-AI collaboration, minimizing risks.

🚀 GenAI Use Cases in Pharma:

  • GenAI applications in research and drug discovery hold transformative potential by shortening processes and predicting successful molecules.
  • Possibilities include designing more effective clinical trials, accelerating patient recruitment, and focusing on efficiency and speed initially.

🔄 Conventional AI/ML Automation:

  • Conventional AI/ML is utilized for non-generative tasks, such as automating clinical data management and identifying errors in clinical trial data.

📈 Pharmaceutical Industry’s Embrace of AI:

  • The pharmaceutical industry is taking AI adoption seriously, with significant investments and a focus on efficiency.
  • Biotech lags behind due to risk aversion, but overall, the industry is optimistic about AI’s potential while recognizing its role as a complement to human expertise.

🩺 AI’s Role in Healthcare Evolution:

  • AI is seen as a tool to accelerate cures and processes, but not a replacement for human scientists or science.
  • Optimism about AI’s contribution to advancements in cancer treatment, with emphasis on collaboration between AI and human expertise.
Sanskruti

Sanskruti Sathe is a passionate healthcare professional author dedicated to improve advancing healthcare knowledge. With over a decade of experience in the field, Sanskruti has worked in various healthcare research institutions. She holds a Master's degree in Public Health and has authored several articles and books on topics ranging from chronic disease management to healthcare policy. As an advocate for evidence-based practice, Sanskruti continues to contribute to the healthcare community through her writing and consulting work.

Recent Posts

Medical Imaging Market Is on the Rising in Europe!

The medical imaging market is witnessing rapid expansion worldwide, and Europe is emerging as a key contributor to this global… Read More

3 hours ago

Continuous Glucose Monitoring (CGM) Devices Market Trends in Canada

The global continuous glucose monitoring devices market size is calculated at USD 4.97 in 2024. Living with diabetes in Canada… Read More

3 hours ago

Surgical Sutures Market Trends in U.S.

The surgical sutures market in the United States is showing steady and promising growth, and here’s why! 👇 👵👴 An… Read More

3 hours ago

Azenta and Frenova Partner to Accelerate Genomic Research in Nephrology Through MyReason® Program

Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More

9 hours ago

Zenara Pharma Receives FDA Approval for First Generic Sertraline Hydrochloride Capsules with 180-Day Marketing Exclusivity

Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More

9 hours ago

Silexion Reports Breakthrough Preclinical Results, Showing Up to 97% Inhibition in KRAS-Driven Cancer Cells

Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data… Read More

9 hours ago